Saint Joseph Hospital

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Metastatic breast cancer3 trials
• Triple-negative breast cancer3 trials
• Melanoma2 trials
• Ovarian cancer2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Gastric and oesophageal cancer1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial

Phase

• Phase 39 trials

Status

• Active, not recruiting10 trials
• Completed2 trials

Lead sponsor

• National Cancer Institute (NCI)9 trials
• ECOG-ACRIN Cancer Research Group1 trial
• NRG Oncology1 trial
• SWOG Cancer Research Network1 trial

Running trials

• Active, not recruiting

  National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

  NCT03939481· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282· Phase 3· National Cancer Institute (NCI)· Source

Closed trials

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source